Literature DB >> 22374795

Human OCTN2 (SLC22A5) is down-regulated in virus- and nonvirus-mediated cancer.

Mariafrancesca Scalise1, Michele Galluccio, Rosita Accardi, Iris Cornet, Massimo Tommasino, Cesare Indiveri.   

Abstract

The expression of carnitine plasma membrane transporter OCTN2 was evaluated in virus and nonvirus-mediated cancer. Both OCTN2 mRNA and protein levels were reduced in keratinocytes retrotransduced with HPV16 E6 and E7 compared with the control. The OCTN2 expression was reduced also in keratinocytes retrotransduced with the sole HPV16 E6. A similar down-regulation of OCTN2 mRNA level was observed in a naturally HPV16-infected cancer cell line, CaSki, harbouring several copies of HPV16 whole genome. The mechanism of down-regulation is not related to p53 transcriptional activity because in SAOS (p53-null) cell line, the restoration of p53 expression did not rescue OCTN2 expression. The treatment of keratinocytes retrotransduced with HPV16 E6 and E7 with 5-aza-cytidine rescued the OCTN2 expression, indicating that the mechanism of down-regulation is linked to DNA methylation. Low levels of mRNA expression of OCTN2 were found also in several nonvirus-related epithelial cancer cell lines. The treatment of those cell lines with 5-aza-cytidine again rescued the expression of OCTN2 as well. These data demonstrate for the first time that the OCTN2 transporter is generally down-regulated in virus and nonvirus-mediated epithelial cancers, probably via methylation of its promoter region.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22374795     DOI: 10.1002/cbf.2816

Source DB:  PubMed          Journal:  Cell Biochem Funct        ISSN: 0263-6484            Impact factor:   3.685


  9 in total

1.  Transcriptional Regulation of Solute Carrier (SLC) Drug Transporters.

Authors:  Shiwei Zhou; Yan Shu
Journal:  Drug Metab Dispos       Date:  2022-05-29       Impact factor: 3.579

Review 2.  A guide to plasma membrane solute carrier proteins.

Authors:  Mattia D Pizzagalli; Ariel Bensimon; Giulio Superti-Furga
Journal:  FEBS J       Date:  2020-09-18       Impact factor: 5.542

3.  Dual targeting of l-carnitine-conjugated nanoparticles to OCTN2 and ATB0,+ to deliver chemotherapeutic agents for colon cancer therapy.

Authors:  Longfa Kou; Qing Yao; Sathish Sivaprakasam; Qiuhua Luo; Yinghua Sun; Qiang Fu; Zhonggui He; Jin Sun; Vadivel Ganapathy
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

4.  Characterization of Exosomal SLC22A5 (OCTN2) carnitine transporter.

Authors:  Lara Console; Mariafrancesca Scalise; Annamaria Tonazzi; Nicola Giangregorio; Cesare Indiveri
Journal:  Sci Rep       Date:  2018-02-28       Impact factor: 4.379

Review 5.  Solute transporters and malignancy: establishing the role of uptake transporters in breast cancer and breast cancer metastasis.

Authors:  Rachel Sutherland; Annette Meeson; Simon Lowes
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

6.  Different involvement of promoter methylation in the expression of organic cation/carnitine transporter 2 (OCTN2) in cancer cell lines.

Authors:  Qiang Qu; Jian Qu; Min Zhan; Lan-Xiang Wu; Yi-Wen Zhang; Xiao-Ya Lou; Li-Juan Fu; Hong-Hao Zhou
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

Review 7.  Membrane transporters in a human genome-scale metabolic knowledgebase and their implications for disease.

Authors:  Swagatika Sahoo; Maike K Aurich; Jon J Jonsson; Ines Thiele
Journal:  Front Physiol       Date:  2014-03-11       Impact factor: 4.566

Review 8.  SLC22A5 (OCTN2) Carnitine Transporter-Indispensable for Cell Metabolism, a Jekyll and Hyde of Human Cancer.

Authors:  Barbara Juraszek; Katarzyna A Nałęcz
Journal:  Molecules       Date:  2019-12-19       Impact factor: 4.411

Review 9.  The Mitochondrial Carnitine Acyl-carnitine Carrier (SLC25A20): Molecular Mechanisms of Transport, Role in Redox Sensing and Interaction with Drugs.

Authors:  Annamaria Tonazzi; Nicola Giangregorio; Lara Console; Ferdinando Palmieri; Cesare Indiveri
Journal:  Biomolecules       Date:  2021-03-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.